Please enter the email address you used to register, then we will send you a link to choose a new password
APGE: 50% | Apogee Announces Interim Results from Phase 1 Healthy Volunteer Trial for APG777, for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule
GTLB: -25% | GitLab Sees Q1 EPS $(0.05)-$(0.04) Vs $0.06 Est.; Revenue $165M-$166M Vs $161.86M Est.; FY25 EPS $0.19-$0.23 Vs $0.35 Est.; Revenue $725M-$731M Vs $731.67M Est.
GANX: 43% | EXCLUSIVE: Gain Therapeutics Tells Benzinga Co. Will Present Data At The AP/PD 2024 Conference On Mar. 8 And 9 Demonstrating Mechanism Of Action Of GT-02287, Its Regulator GCase Regulator For The Treatment Of Parkinson's Disease
Posted In: APGE GANX GTLB